Pharmacokinetic interactions between three SGLT2 inhibitors and telmisartan: A focus on empagliflozin, ertugliflozin, and henagliflozin

Xin Zhou, Yanru Deng, Caihui Guo, Ying Li, Yuhao Fu, Zhi Wang, Zhanjun Dong · 2026

Read Pharmacokinetic interactions between three SGLT2 inhibitors and telmisartan: A focus on empagliflozin, ertugliflozin, and henagliflozin by Xin Zhou, Yanru Deng, Caihui Guo, Ying Li, Yuhao Fu, Zhi Wang, Zhanjun Dong (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0350400.txt.

Description

Xin Zhou and colleagues checked, in rats, whether a common blood pressure drug changes how the body handles three newer diabetes drugs, since patients often take both. All four drugs cross paths with the same cellular pumps that move medicines through gut, liver, and kidney. Twelve groups of rats received the drugs singly and in pairs, with blood levels tracked by sensitive instruments.

The blood pressure drug, telmisartan, raised blood levels of two of the diabetes drugs, empagliflozin and henagliflozin, while slowing their clearance. Run the pairing the other way, two diabetes drugs lowered telmisartan levels. The team also showed the interactions at the gene level, with pump expression turned down in several organs. Rat results do not set human doses, but they flag pairs worth watching when both prescriptions sit on one chart.

Catalog record

CREATORXin Zhou, Yanru Deng, Caihui Guo, Ying Li, Yuhao Fu, Zhi Wang, Zhanjun Dong
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47510
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0350400

Browse the full library · About the Tower of Babel